Coronavirus vaccine is being developed by Janssen Pharmaceutical by using its AdVac® and PER.C6® technologies for the treatment and prevention of COVID-2019 infections. AdVac® and PER.C6® technologies helps to increase the production of optimal vaccine candidate. Preclinical development is underway in the US.
In April 2020, Catalent entered into a manufacturing agreement with the Janssen Pharmaceutical Companies of Johnson & Johnson, to accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing for COVID-19 vaccine. The collaboration commits joint investment to accelerate rapid scale-up of segregated manufacturing capacity to support dedicated production of the vaccine 
In April 2020, Janssen Pharmaceutical and Emergent BioSolutions entered into an agreement to support manufacturing of COVID-2019 vaccine. The agreement designed to accelerate manufacturing of the vaccine. Johnson & Johnson will invest to expand drug substance capacity related to the vaccine candidate. Emergent will provide drug substance manufacturing services, valued at approximately $US135 million, beginning in 2020, and will reserve operations capacity to potentially support commercial manufacturing of the vaccine leveraging Janssen's proven AdVac® and PER.C6® technologies beginning in 2021. Financial terms of the agreement were not disclosed.  
In February 2020, Janssen Pharmaceutical expanded its existing collaboration with Biomedical Advanced Research and Development Authority (BARDA) to seek treatment solutions for COVID-2019 infections. The collaboration will enhance Janssen's ongoing work with global partners to screen a library of existing antiviral molecules, with the aim of identifying compounds with promising antiviral activity against coronavirus. Earlier, in the same month, Janssen Pharmaceutical entered into a collaboration with the BARDA to expedite its new coronavirus vaccine programme. Under the terms of the agreement, Janssen and BARDA will both contribute to the research and development costs and mobilise resources to rapidly advance the initial stages of Janssen's COVID-19 vaccine development programme. BARDA will provide funding to support accelerated development of a vaccine candidate into phase I studies, with options for additional funding to progress a promising candidate. The company will work with the Rega Institute for Medical Research (KU Leuven), in Belgium. The arrangement couples the Institute's infrastructure, breadth of high throughput screening experience, and capabilities for studying special pathogens with Janssen's drug development resources and antiviral expertise. In parallel, Janssen will work to upscale the production and manufacturing capacities required to meet public health needs.
Key Development Milestones
In March 2020, Janssen Pharmaceutical announced the selection of a lead COVID-19 vaccine candidate from various constructs. The company also announced its intention to initiate vaccine production at risk imminently to make it available on a not-for-profit basis for emergency pandemic use. Earlier in the same month Janssen reported initiation of preclinical testing of multiple vaccine prospects, to identify a coronavirus vaccine for clinical trials   .
In January 2020, Janssen Pharmaceutical initiated research on coronavirus vaccine  .
In March 2020, Johnson & Johnson and BARDA together committed more than $US1 billion for research and development of the coronavirus vaccine. Both the organisations independently provided additional funding that will enable expansion of their ongoing work to identify potential antiviral treatments against coronavirus  .